About this raise

Med-X, with a pre-money valuation of $102 million, is raising funds on Dalmore via Regulation A+. The company has developed many all-natural and plant-based brands that are replacing chemicals to solve everyday issues. The products are sold through major retail and healthcare distributors. The flagship product lines of Med-X include Nature-Cide and Thermal-Aid. Med-X is led by Dr. David Toomey and Matthew Mills and was founded in 2014.

Expand

Investment Overview

Invested this round: $3,936,422

Deal Terms

Total Commitments ($USD)

Platform
Dalmore Group
Start Date
07/23/2021
Close Date
Not Provided
Min. Goal
$420
Max Goal
$10,000,000
Min. Investment

$420

Security Type

Equity - Common

Series

Series A

SEC Filing Type

RegA+    Open SEC Filing

Price Per Share

$0.80

Pre-Money Valuation

$102,217,405

Company & Team

Company

Year Founded
2014
Industry
Consumer Products, Goods & Services
Tech Sector
Cleantech
Distribution Model
B2B2C
Margin
Medium
Capital Intensity
High
Location
Canoga Park, California
Business Type
Growth
Company Website
Visit Website

Team

Employees
14
Prior Founder Exits?
No
Founder Name
Matthew Mills
Title
CEO

Financials

 Revenue +29% YoY
$1,033,750
 Monthly Burn
$254,167
 Runway
3 months

Balance Sheet

Cash and Cash Equivalents

$752,823

Investment Securities

$0

Accounts and Notes Receivable

$150,929

Property, Plant and Equipment (PP&E)

$81,971

Total Assets

$3,081,150

Accounts Payable & Accrued Liabilities

$352,317

Long Term Debt

$1,156,573

Total Liabilities

$2,194,674

Total Stockholders' Equity

$886,476

Total Liabilities and Equity

$3,081,150

Statement of Comprehensive Income Information

Total Revenues

$1,033,750

Costs & Expenses Applicable to Rev

$711,820

Depreciation and Amortization

$115,398

Net Income

$-3,050,009

Earnings Per Share - Basic

$-0.03

Earnings Per Share - Diluted

$-0.03

Auditor: Prager Metis, CPA's LLP
Create a free account today to gain access to Kingscrowd analytics and financials.

Upgrade to gain access

Pay Monthly
Annually (2 months free)

Edge

$12.50 /month
billed annually
Free portfolio tracking, data-driven ratings, AI analysis and reports
Plan Includes:
Everything in Free, plus
Company specific Kingscrowd ratings and analyst reports
Deal explorer and side-by-side comparison
Startup exit and failure tracking
Startup market filters and historical industry data
Advanced company search ( with ratings)
Get Edge Annual
Already a member? Log in here.

Ratings Kingscrowd Startup Rating Methodology Article

Blurred Ratings Bars Blurred Ratings Bars

Company Funding & Growth

Funding history

Close Date Platform Valuation Total Raised Security Type Status Reg Type
05/27/2025 DealMaker Securities $50,894,025 $1,022,943 Equity - Common Active RegCF
11/09/2023 Dalmore Group $102,217,405 $3,936,422 Equity - Common Funded RegA+
05/23/2023 PicMii $43,211,544 $0 Equity - Common Not Funded RegCF
09/10/2021 truCrowd $88,552,772 $15,595 Equity - Common Funded RegCF
06/27/2019 StartEngine - $7,000,471 Equity - Common Funded RegA+
Create a free account today to gain access to Kingscrowd analytics.

Growth Charts

Revenue History

Note: Revenue data points reflect the latest of either the most recent fiscal year's financials, or updated revenues directly from the founder, at each raise's close date.

Valuation History

Price per Share History

Note: Share prices shown in earlier rounds may not be indicative of any stock splits.

Employee History

Founders: enhance your startup's credibility on Kingscrowd. Create an account to claim this raise page.
Add to portfolio
Med-X on Dalmore Group 2021
Platform: Dalmore Group
Security Type: Equity - Common
Valuation: $102,217,405
Price per Share: $0.80

Follow company

Follow Med-X on Dalmore Group 2021

Buy Med-X's Deal Report

Warning: according to the close date for this deal, Med-X may no longer be accepting investments.

Med-X Deal Report

Get Kingscrowd's comprehensive report on Med-X including:

  • How our proprietary algorithm rates their current capital raise (1-5 stars)
  • Detailed price, market, team, differentiators, performance, and risk ratings
  • Whether Med-X is undervalued or overvalued
  • Scores on the founding team and key personnel's background and expertise

Buy the Med-X deal report for only $10!

Email address:
Looking to buy more than one deal report? Get unlimited reports by upgrading to Edge